Medical Options for Advanced HFpEF/HFmrEF Patients: Patient Cases

Published: 13 August 2024

  • Views:

    Views Icon 2424
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Part one of this programme explores two interactive case studies on advanced treatment options for HFpEF and HFmrEF from Prof Pardeep Jhund (University of Glasgow, UK) and Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, US). We encourage you to submit your answers on treatment options in the provided polls.

 

These results will support part two of the programme, An Expert-Guided Virtual Ward Round. In the upcoming live roundtable, leading specialists will analyse the responses, providing detailed insights into prevailing clinical practices and potential areas for improvement. The experts will then share their own perspectives on the presented cases, drawing on their extensive experience and knowledge to offer guidance and recommendations.

 

This programme will support you to stay at the forefront of clinical practice advancements. Join us to enhance your knowledge and improve patient care. Your participation is key – submit your answers today. 

 

Register for part two to join the live discussion.

 

 

 This education was developed by Radcliffe Medical Communications (Eire) Ltd.

This programme is supported by an unrestricted educational grant from Bayer.

Learning Objectives

  • Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
  • Select appropriate patients for advanced medical therapy
  • Recall recent trial data for novel therapeutic approaches
  • Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF

Target Audience

  • Cardiologists
  • Internists
  • Heart Failure Specialists
  • General Practitioners
  • Nurse Practitioners
  • Cardiovascular Nurses
  • Allied Healthcare Professionals

More from this programme

Part 1

Case Study

In this video, Prof Pardeep Jhund presents a case study of a patient with preserved ejection fraction and CKD stage 3.

Part 2

Case Study

In this video, Dr Muthiah Vaduganathan presents a case study of a HFpEF patient. 

About the episode

Dr Muthiah Vaduganathan presents a case study of a HFpEF patient with a history of heart failure and with dyspnea on exertion and recent onset palpitations. The patient undergoes TEE and is diuresed with intravenous furosemide. Dr Vaduganathan asks, ‘Do you have any other recommendations for optimisation prior to hospital discharge?'.

Vote in the poll below or via the survey link here.

 

Faculty Biographies

Muthiah Vaduganathan

Muthiah Vaduganathan

Co-Director, Center for Cardiometabolic Implementation Science

Dr Muthiah Vaduganathan is a Cardiologist and Clinical Trialist at Brigham and Women’s Hospital and Harvard Medical School, Boston, US. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies, and he has authored or co-authored more than 700 peer-reviewed publications. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.